Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie S Callander

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|March 12, 2021
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significanceJorge J Castillo, Natalie S Callander, Muhamed Baljevic, et al.
Anticancer Research|September 29, 2020
Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple MyelomaThejus Jayakrishnan, Veli Bakalov, Natalie S Callander, et al.
Blood|February 1, 2003
AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myelomaSun J Choi, Tomoko Oba, Natalie S Callander, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 26, 2020
Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all?Olivia M Kim, Jason R Jared, Emily R Hennes, et al.
Plos One|December 8, 2022
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugsMailee Huynh, Hae Yeun Chang, Dominique N Lisiero, et al.
Endocrinology|September 11, 2019
Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant ActivityDavid K Lung, Jay W Warrick, Peiman Hematti, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Blood|January 21, 2012
Microscale functional cytomics for studying hematologic cancersEdmond W K Young, Chorom Pak, Brad S Kahl, et al.
Transplantation and Cellular Therapy|November 15, 2023
PD1<sup>+</sup>TIGIT<sup>+</sup>2B4<sup>+</sup>KLRG1<sup>+</sup> Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell TherapyAmeet K Mishra, Timothy M Schmidt, Ella B Martell, et al.
Integrative Cancer Science and Therapeutics|December 14, 2019
Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patientsAmanda Graul-Conroy, Margo Hoover-Regan, Kenneth B DeSantes, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|March 12, 2021
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significanceJorge J Castillo, Natalie S Callander, Muhamed Baljevic, et al.
Anticancer Research|September 29, 2020
Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple MyelomaThejus Jayakrishnan, Veli Bakalov, Natalie S Callander, et al.
Blood|February 1, 2003
AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myelomaSun J Choi, Tomoko Oba, Natalie S Callander, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 26, 2020
Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all?Olivia M Kim, Jason R Jared, Emily R Hennes, et al.
Plos One|December 8, 2022
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugsMailee Huynh, Hae Yeun Chang, Dominique N Lisiero, et al.
Endocrinology|September 11, 2019
Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant ActivityDavid K Lung, Jay W Warrick, Peiman Hematti, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Blood|January 21, 2012
Microscale functional cytomics for studying hematologic cancersEdmond W K Young, Chorom Pak, Brad S Kahl, et al.
Transplantation and Cellular Therapy|November 15, 2023
PD1<sup>+</sup>TIGIT<sup>+</sup>2B4<sup>+</sup>KLRG1<sup>+</sup> Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell TherapyAmeet K Mishra, Timothy M Schmidt, Ella B Martell, et al.
Integrative Cancer Science and Therapeutics|December 14, 2019
Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patientsAmanda Graul-Conroy, Margo Hoover-Regan, Kenneth B DeSantes, et al.
Pageof 10